July 30, 2009 to August 02, 2009
This is an accordion element with a series of buttons that open and close related content panels.
Schedule
Thursday, July 30, 2009
4:00 – 5:45 pm – Reception and Registration – Pick up conference materials at Khorana Auditorium (Room 175 Biochemistry Addition, 433 Babcock Drive)
Session 1 – General
6:00pm – Welcome
Aseem Ansari, UW-Madison
6:05pm – 6:20pm – Comments
Chair: Uttam RajBhandary, MIT
6:20pm – 6:40pm Nucleic Acid Chemistry: From Gobind to the Present – Video
Marvin Caruthers, University of Colorado – Boulder
6:40pm – 7:00pm Viral Membrane Fusion and its Inhibition – Video
Peter Kim, Merck
7:00pm – 7:20pm The Metabolism and Function of Dehydroepiandrosterone – Video
Henry Lardy, UW-Madison
7:20pm – 7:40pm Deciphering the Genetic Code – Video
Marshall Nirenberg, National Institute of Health
7:40pm – 8:00pm Regulation of Tumor Metastasis by MAP Kinase and MicroRNAs
Marsha Rosner, University of Chicago
Friday, July 31, 2009
Session 2 – Nucleic Acids
8:30am – Continental Breakfast
9:00am – 9:05am – Comments
Chair: Hara Ghosh
9:05am – 9:25am Non-B DNA Conformations, Mutagenesis and Disease – Video
Robert Wells, Texas A&M
9:25am – 9:45am Bisulfite Modification of Nucleotides: Mechanistic Consideration leading to improved Protocols of DNA Methylation Analysis – Video
Hikoya Hayatsu, Okayama University
9:45am – 10:05am The Puzzle of Prophage λ Stability – Video
Sankar Adhya, National Cancer Institute
10:05am – 10:25am The Genetic Code Revisited – Four Decades after Francis Crick – Video
Dieter Söll, Yale
10:25am – 10:45am – Coffee Break
10:45am – 10:50am – Comments
Chair: Takao Sekiya
10:50am – 11:10am One RNA Aptamer Sequence, Two Structures: A Collaborating Pair that Competitively Inhibits AMPA Receptors – Video
Li Niu, University at Albany
11:10am – 11:30am The Hopeful Cornucopia – A study into Combinatorial Gene Synthesis – Video
Hans-Joachim Fritz, Georg-August-Univsitat
11:30am – 11:50am Efficient Synthesis of Oligonucleotide Conjugates on Solid-Support Using an (Aminoethoxycarbonyl) aminohexyl Group for 5’-Terminal Modification – Video
Eiko Ohtsuka, AIST
11:50am – 12:10pm The First Crystallographic Structure of Mammalian Phosphofructokinase from Rabbit Skeletal Muscle – Video
Simon Chang, LSU
12:10pm – 1:45pm – Lunch and Poster Session
Session 3 – Membranes, Receptors and Signaling
1:45pm – 1:50pm – Comments
Chair: Pere Garriga
1:50pm – 2:10pm Gobind Khorana and My Current Research on Drosophila Behavior – Video
Julius Adler, UW-Madison
2:10pm – 2:30pm Oxygen Control of Cyclic di-GMP Homeostasis – Video
Marie-Alda Gilles-Gonzalez, UT Southwestern
2:30pm – 2:50pm Gobind Khorana and the “Central Dogma” of Receptor Activation – Video
Wayne Hubbell, UCLA
2:50pm – 3:10pm Heptahelical Receptors: Ligand Recognition and Conformational Dynamics in Bilayers – Video
Thomas Sakmar, Rockefeller
3:10pm – 3:30pm Dynamics of G-Protein Coupled Receptor (GPCR) Activation and Attenuation: Insights from Fluorescence Studies – Video
David Farrens, Oregon Health & Science
3:30pm – 4:00pm – Break
4:00pm – 4:05pm – Comments
Chair: Umesh Varshney
4:05pm – 4:25pm Pharmacogenetics of the Human Prostacyclin Receptor: “hIP, SNiP COX and Vioxx” – Video
John Hwa, Dartmouth
4:25pm – 4:45pm Signaling via Structure Change: NMR Analysis of GPCR and G protein Activation – Video
Kevin Ridge, University of Texas
4:45pm – 5:05pm Learning from Rhodopsin about Metabotropic Glutamate Receptors – Video
Judith Klein-Seetharaman, University of Pittsburgh
5:05pm – 5:25pm Oncogenic Kit Receptor Signaling and Targeted Molecular Therapies – in Mouse Models of Gastrointestinal Stromal Tumor – Video
Peter Besmer, Sloan-Kettering
6:00pm – 10:00pm – Madison Club Reception
Saturday, August 1, 2009
Session 4 – Genes and Regulation
8:00am – Continental Breakfast
8:25am – 8:30am – Comments
Co-Chairs: Molly Jahn & Masayasu Nomura
8:30am – 8:55am Binding Reactions: Epigenetic Switches, Signal Transduction, Evolution and Cancer – Video
Mark Ptashne, Sloan Kettering
8:55am – 9:20am Transcription Factors as Targets for Cancer Therapy – Video
Peter Dervan, Caltech
9:20am – 9:45am RNA as a Gene Regulation Modality – Video
Phillip Sharp, MIT
9:45am – 10:05am Dissecting the roles of X. laevis miRNAs and Ago proteins in RISC activity – Video
James Dahlberg, UW-Madison
10:05am – 10:30am Large Structured Non-coding RNAs Revealed by Bacterial Metagenome Analysis – Video
Ronald Breaker, Yale
10:30am – 10:45am – Coffee Break
Session 5 – Genomes, Networks, Systems and Molecular Medicine
10:45am – 10:50pm – Comments
Chair: Lloyd Smith
10:50am – 11:15am Systems Biology, Transforming Technologies and the Emergence of P4 Medicine (Predictive, Personalized, Preventive and Participatory) – Video
Lee Hood, Systems Biology
11:15am – 11:40am Programming Cell State – Video
Richard Young, Whitehead Institue – MIT
11:40am – 12:05pm The “Dark Matter” of Biological Regulation? – Video
Patrick Brown, Stanford
12:05pm – 12:25pm Acquired Stress Resistance in Yeast: Multiple Means to the Same End – Video
Audrey Gasch, UW-Madison
12:30pm – 2:30pm – Lunch and Poster Session (Continued)
Session 6 – Rewiring Cell Fate and Signaling Pathways
2:30pm – 2:35pm – Comments
Chair: Jennifer Reed
2:35pm – 2:55pm Human Induced Pluripotent Stem Cells Derived with Episomal Vectors – Video
James Thomson, UW-Madison
2:55pm – 3:20pm Biological Innovation: The Evolution and Engineering of New Signaling Systems – Video
Wendell Lim, UCSF
3:20pm – 3:40pm Chemical Probes of Receptor Assembly in Signaling – Video
Laura Kiessling, UW-Madison
Session 7 – Rewiring Genes and Networks (Biofuels)
3:40pm – 3:45pm – Comments
Chair: Tim Donohue
3:45pm – 4:10pm Synthetic Biology for Synthetic Fuels – Video
Jay Keasling, Berkley
4:10pm – 4:30pm Genome-scale Chromosomal Engineering of Bacterial Hosts for Bioenergy Production – Video
Robert Landick, UW-Madison
4:30pm – 4:45pm – Break
Session 8A – Origins and Designing Life – Synthetic Life
4:45pm – 4:50pm – Comments
Chair: Aseem Ansari
4:50pm – 5:15pm Making a Synthetic Cell – Video
Hamilton Smith, J. Craig Venter Institute
5:15pm – 5:40pm Reading and Writing Genomes – Video
George Church, Harvard Medical
5:40pm – 6:05pm Questions about Questions about the Origin of Life – Video
George Whitesides, Harvard
6:05pm – 6:30pm Synthetic Biology in Ethical Perspective – Video
Alta Charo, UW-Madison
7:00pm – 9:00pm – Banquet (Pyle Center – Alumni Lounge, 702 Langdon Street)
Violin Concerto – Ptashne with Adrian Levine & Sara Sitzer
Banquet speaker: William Dove
Sunday, August 2, 2009
Session 8B – Origins and Designing Life – Synthetic Genes and Genomes
8:00am – 8:25am – Continental Breakfast
8:25am – 8:30am – Comments & Synthetic multi-cullular systems biology – Video
Chair: Eric Werner
8:30am – 8:50am Reducing the genome of E. coli: a top down approach to synthetic biology – Video
Fredrich Blattner, UW-Madison
8:50am – 9:15am To Be Announced – Video
Thomas Knight, MIT
9:15am – 9:40am The Physics of Genome Management – Video
Rob Phillips, Caltech
Session 9 – Nano-Devices and Biomachines
9:40am – 9:45am – Comments
Co-Chairs: Franco Cerrina & George Phillips
9:45am – 10:10am DNA: Not Merely the Secret of Life – Video
Nadrian Seeman, New York University
10:10am – 10:35am Programmable Self-assembly of DNA into Nanoscale Three-dimensional Shapes – Video
William Shih, Harvard Medical
10:35am – 10:55am Top Down Meets Bottom Up: Controlled Placement of DNA Nanostructures – Video
Ryan Kershner, UW-Madison
Session 10 – Development, Disease and Drug Design
10:55am – 11:00am – Comments
Co-Chairs: James Ntambi & Hasan Mukhtar
11:00am – 11:25am Transcriptional Precision in the Drosophila Embryo – Video
Michael Levine, Berkeley
11:25am – 11:45am Gene Networks and Type 2 Diabetes – Video
Alan Attie, UW-Madison
11:45am – 12:05pm Direct Inhibition of the Notch Transactivation Complex – Video
James Bradner, Dana-Farber Cancer Institute
12:05pm – 12:25pm – Closing Remarks
Waclaw Szybalski, UW-Madison
Organizers
Speakers
Aseem Ansari – UW-Madison – Co-Organizer
Uttam RajBhandary – MIT – Co-Organizer
Sankar Adhya – National Cancer Institute
Julius Adler – UW-Madison
Alan Attie – UW-Madison
Peter Besmer – Sloan-Kettering
Fredrick Blattner – UW-Madison
James Bradner – Dana-Farber Cancer Institute
Ronald Breaker – Yale
Patrick Brown – Stanford
Marvin Caruthers – University of CO-Boulder
Simon Chang – LSU
Alta Charo – UW-Madison
George Church – Harvard Medical
James Dahlberg – UW-Madison
Peter Dervan – Caltech
William Dove – UW-Madison
David Farrens – Oregon Health & Science
Hans-Joachim Fritz – Georg-August-Universitat
Audrey Gasch – UW-Madison
Marie-Alda Gilles-Gonzalez – UT Southwestern
Hikoya Hayatsu – Okayama University
Lee Hood – Systems Biology
Wayne Hubbell – UCLA
John Hwa – Dartmouth
Jay Keasling – Berkeley
Ryan Kershner – UW-Madison
Laura Kiessling – UW-Madison
Peter Kim – Merck
Judith Klein-Seetharaman – University of Pittsburgh
Thomas Knight – MIT
Robert Landick – UW-Madison
Henry Lardy – UW-Madison
Michael Levine – Berkeley
Wendell Lim – UCSF
Marshall Nirenberg – National Institute of Health
Li Niu – University at Albany
Eiko Ohtsuka – AIST
Rob Phillips – Caltech
Mark Ptashne – Sloan Kettering
Kevin Ridge – University of Texas
Marsha Rosner – University of Chicago
Thomas Sakmar – Rockefeller
Nadrian Seeman – New York University
Phillip Sharp – MIT
William Shih – Harvard Medical
Hamilton Smith – J. Craig Venter Institute
Dieter Söll – Yale
Waclaw Szybalski – UW-Madison
James Thomson – UW-Madison
Robert Wells – Texas A&M
George Whitesides – Harvard
Richard Young – Whitehead Institute MIT
Sponsors
As the private, nonprofit patent and licensing organization for the University of Wisconsin-Madison, the Wisconsin Alumni Research Foundation (WARF) was established as the world’s first university-based technology transfer organization in 1925. It was founded by UW-Madison professor and inventor Harry Steenbock to ensure that his breakthrough discovery for increasing the Vitamin D content of foods was commercialized for societal benefit, and to ensure that proceeds from his invention supported university research. WARF has continued to fulfill Dr. Steenbock’s vision for the past 84 years, during which it has processed approximately 6,000 university inventions, completed 1,600 license agreement and gifted the UW-Madison nearly $1 billion generated from its licensing and investment revenues.
The vision of the private, nonprofit Morgridge Institute for Research, part of the Wisconsin Institutes for Discovery opening in 2010 on the University of Wisconsin-Madison campus, is to enhance the university’s already considerable strengths in interdisciplinary biomedical research and accelerate the process of “Discovery to Delivery ” to improve human health. The Morgridge Institute is committed to building a collaborative research capability that integrates world-class basic science, initially focused on the challenge areas of regenerative biology and virology, through a strong cyberinfrastructure core and cutting edge innovation in science education.
Alnylam Pharmaceuticals is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is applying its therapeutic expertise in RNAi to address significant medical needs, many of which cannot effectively be addressed with small molecules or antibodies, the current major classes of drugs. Alnylam is leading the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature, Nature Medicine, and Cell. The company is leveraging these capabilities to build a broad pipeline of RNAi therapeutics; its most advanced program is in Phase II human clinical trials for the treatment of respiratory syncytial virus (RSV) infection and is partnered with Cubist and Kyowa Hakko Kirin. In addition, the company is developing RNAi therapeutics for the treatment of a wide range of disease areas, including liver cancers, hypercholesterolemia, Huntington’s disease, and TTR amyloidosis. The company’s leadership position in fundamental patents, technology, and know-how relating to RNAi has enabled it to form major alliances with leading companies including Medtronic, Novartis, Biogen Idec, Roche, Takeda, Kyowa Hakko Kirin, and Cubist. To reflect its outlook for key scientific, clinical, and business initiatives, Alnylam established “RNAi 2010” in January 2008 which includes the company’s plan to significantly expand the scope of delivery solutions for RNAi therapeutics, have four or more programs in clinical development, and to form four or more new major business collaborations, all by the end of 2010. Alnylam and Isis are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA-based therapeutics. Founded in 2002, Alnylam maintains headquarters in Cambridge, Massachusetts. For more information, please visit www.alnylam.com.
In 1998 the Genome Center of Wisconsin (GCW) was established at the University of Wisconsin-Madison. The Genome Center, located at 425 Henry Mall, is a research center existing within the University of Wisconsin Biotechnology Center.
The Genome Center’s 42 faculty members represent over 17 departments and six schools within the University of Wisconsin-Madison. The Genome Center fosters integrative and highly collaborative research that bridges multiple, diverse disciplines. Faculty members are involved in genomic research, graduate and undergraduate teaching, and pre- and post-doctoral training.
In September 2004, GCW faculty and members moved into state-of-the-art laboratories and office space designed to foster interdisciplinary research collaborations working to create solutions to biological problems raised by genome data. There are four main divisions of study under genomics, which are Genome Sequencing, Functional Genomics, Comparative Genomics, and Bioinformatics.
The UW–Madison Stem Cell and Regenerative Medicine Center (SCRMC) is an umbrella organization operating under the School of Medicine and Public Health and the Graduate School. The SCRMC provides a central point of contact, information and facilitation for all stem cell research activities on campus.
The center’s mission is to advance the science of stem cell biology and foster breakthroughs in regenerative medicine through faculty interactions, research support and education.
Our Goals:
- Maintain UW-Madison as leader in stem cell and regenerative medicine research and application.
- Foster increased SCRM communication within campus and beyond its borders.
- Support SCRM research: basic, translational, clinical, bioethics, and public policy.
- Develop educational, training and outreach programs
- Enhance philanthropic support.
The University of Wisconsin-Madison offers a predoctoral training program in biotechnology. The objective of this program is to educate a new cadre of scientists and engineers whose training and experience cross traditional disciplinary boundaries. The National Institutes for Health has awarded thirty traineeships to this program, with about ten per year available to award. More than 140 faculty serve as trainers from 46 different departments and 6 UW School and Colleges. Trainees receive Ph.D. degrees in their chosen field, such as microbiology, chemistry, pharmacology, molecular biology, chemical engineering, mathematics, biomedical engineering or computer science. Students minor in a cross discipline, for instance a chemical engineer would take classes in biology, and vice versa. Trainees each presents a seminar annually about thesis research or internship experience, and each trainee participates in an industrial or national laboratory internship sometime during their program support. To date, internships have been completed by one sixty-five trainees at sixty-nine biotechnology companies and ten national laboratories, to great mutual benefit. Of the one hundred seventy-eight BTP doctoral graduates, all are now employed in industry, in academia, or as post-doctoral fellows.
The Computation and Informatics in Biology and Medicine (CIBM) Training Program at UW-Madison is an interdisciplinary predoctoral and postdoctoral bioinformatics training program, funded by a grant from The National Library of Medicine (No. 5T15LM007359), with additional support from the University of Wisconsin Graduate School and departments across campus. The CIBM mission is to provide modern training for a new generation of researchers wishing to solve biomedical problems requiring strengths in both computational and biological science. This training program is one of just 19 institutional training programs in biomedical informatics in the U.S. The 52 CIBM faculty span 15 different departments and five colleges at UW-Madison as well as several faculty at the Marshfield Clinic Research Foundation (located about 100 miles north of Madison).
The Genomic Sciences Training Program (GSTP) is a new interdisciplinary predoctoral and postdoctoral training program at the University of Wisconsin-Madison, funded by a grant from the National Institutes of Health/National Human Genome Research Institute. Additional support is provided by the UW Graduate School and the Genome Center/Biotechnology Center.
The mission of the GSTP is to train the next generation of genomicists, enabling them to gain strengths to bridge multiple disciplines needed for an integrated approach to solving complex problems in genomics research. These disciplines include chemistry, engineering, computer science, biostatistics, genetics, biochemistry, molecular medicine, and molecular biology.
Established in the mid-1970s as a cooperative laboratory of experienced scientists, New England Biolabs (NEB) is a world leader in the production and supply of reagents for the life science industry. NEB now offers the largest selection of recombinant and native enzymes for genomic research and continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis, markers and ladders, competent cells and RNA analysis.
At 35 years old, New England Biolabs can be considered one of the first companies to help shape today’s biotechnology industry. Housed in a new state-of-the-art facility, our USA headquarters includes a modern fermentation center and fully equipped laboratories for production, quality control, product development and basic research. As one of the first companies to produce restriction enzymes on a commercial scale, NEB continues to specialize in restriction enzymes and consistently maintains a position at the forefront of this field. At New England Biolabs, science has always been a priority and through this approach, our reagents have gained a world-wide reputation for setting the highest of standards for quality and value.
Gifts/Donations
If you are interested in making a gift or donation to the symposium fund, please visit the Biochemistry specific UW Foundation page. On the Foundation web page please add “for Steenbock Symposium” after the green Department of Biochemistry (1215105) text.